Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges

References

• Motzer RJ, Escudier B, McDermott D, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813. doi:10.1056/NEJMoa151066526406148
   PubMed Web of Science ®Google Scholar
• Varricchi G, Galdiero MR, Marone G, et al. Cardiotoxicity of immune checkpoint inhibitors. ESMO Open. 2017;2:4. doi:10.1136/esmoopen-2017-000247
   Web of Science ®Google Scholar
• Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291:319–322. doi:10.1126/science.291.5502.31911209085
   PubMed Web of Science ®Google Scholar
• Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 2003;9:1477–1483. doi:10.1038/nm95514595408
   PubMed Web of Science ®Google Scholar
• Lucas JA, Menke J, Rabacal WA, Schoen FJ, Sharpe AH, Kelley VR. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J Immunol. 2008;181:2513–2521.18684942
   PubMed Web of Science ®Google Scholar
• Wang J, Okazaki IM, Yoshida T, et al. PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int Immunol. 2010;22:443–452. doi:10.1093/intimm/dxq02620410257
   PubMed Web of Science ®Google Scholar
• Frigeri M, Meyer P, Banfi C, et al. Immune checkpoint inhibitor-associated myocarditis: a new challenge for cardiologists. Can J Cardiol. 2018;34(1):92.e1–92.e3. doi:10.1016/j.cjca.2017.12.015
   PubMed Web of Science ®Google Scholar
• Tajmir-Riahi A, Bergmann T, Schmid M, Agaimy A, Schuler G, Heinzerling L. Life-threatening autoimmune cardiomyopathy reproducibly induced in a patient by checkpoint inhibitor therapy. J Immunother. 2018;41(1):35–38. doi:10.1097/CJI.000000000000019029077601
   PubMed Web of Science ®Google Scholar
• Norwood TG, Westbrook BC, Johnson DB, et al. Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer. 2017;5(1):91. doi:10.1186/s40425-017-0296-429157297
   PubMedGoogle Scholar
• Chen Q, Huang DS, Zhang LW, Li YQ, Wang HW, Liu HB. Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma. Clin Toxicol (Phila). 2018;56(7):667–671. doi:10.1080/15563650.2017.140107929126352
   PubMed Web of Science ®Google Scholar
• Fukusawa Y, Sasaki K, Natsume M, et al. Nivolumab-induced myocarditis concomitant with myasthenia gravis. Case Rep Oncol. 2017;10(3):809–812. doi:10.1159/00047995829070994
   PubMedGoogle Scholar
• Matson DR, Accola MA, Rehrauer WM, Corliss RF. Fatal myocarditis following treatment with the PD-1 inhibitor nivolumab. J Forensic Sci. 2018;63(3):954–957. doi:10.1111/1556-4029.1363328833116
   PubMed Web of Science ®Google Scholar
• Sauer R, Kiewe P, Desole M, et al. Lymphocytic myocarditis in a patient with metastatic clear cell renal cell carcinoma treated with nivolumab. Pathologe. 2017;38(6):535–539. doi:10.1007/s00292-017-0349-y28819833
   PubMed Web of Science ®Google Scholar
• Tay RY, Blackley E, Mc Lean C, et al. Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. Br J Cancer. 2017;117(7):921–924. doi:10.1038/bjc.2017.25328797029
   PubMed Web of Science ®Google Scholar
• Behling J, Kaes J, Münzel T, Grabbe S, Loquai C. New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma. Melanoma Res. 2017;27(2):155–158. doi:10.1097/CMR.000000000000031427977496
   PubMed Web of Science ®Google Scholar
• Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–1755. doi:10.1056/NEJMoa160921427806233
   PubMed Web of Science ®Google Scholar
• Tadokoro T, Keshino E, Makiyama A, et al. Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab. Circ Heart Fail. 2016;9(10). doi:10.1161/CIRCHEARTFAILURE.116.003514
   PubMed Web of Science ®Google Scholar
• Semper H, Muehlberg F, Schulz-Menger J, Allewelt M, Grohé C. Drug-induced myocarditis after nivolumab treatment in a patient with PDL1-negative squamous cell carcinoma of the lung. Lung Cancer. 2016;99:117–119. doi:10.1016/j.lungcan.2016.06.02527565924
   PubMed Web of Science ®Google Scholar
• Gibson R, Delaune J, Szady A, et al. Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer. BMJ Case Rep. 2016;2016. doi:10.1136/bcr-2015-212769
   PubMedGoogle Scholar
• Kimura T, Fukushima S, Miyashita A, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci. 2016;107(7):1055–1058. doi:10.1111/cas.1296127420474
   PubMed Web of Science ®Google Scholar
• Mehta A, Gupta A, Hannallah F, Koshy T, Reimold S. Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma. Melanoma Res. 2016;26(3):319–320. doi:10.1097/CMR.000000000000025127110676
   PubMed Web of Science ®Google Scholar
• Gill DM, Hahn AW, Hale P, Maughan BL. Overview of current and future first-line systemic therapy for metastatic clear cell renal cell carcinoma. Curr Treat Options Oncol. 2018;19(1):6. doi:10.1007/s11864-018-0517-129368125
   PubMed Web of Science ®Google Scholar
• Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpointinhibitor-associated myocarditis. Lancet. 2018;391(10124):933. doi:10.1016/S0140-6736(18)30302-7
   PubMed Web of Science ®Google Scholar
• Sarocchi M, Grossi F, Arboscello E, et al. Serial troponin for early detection of nivolumab cardiotoxicity in advanced non-small cell lung cancer patients. Oncologist. 2018;Pii:2017–2452.
   Google Scholar
• Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017;89(11):1127–1134. doi:10.1212/WNL.000000000000435928821685
   PubMed Web of Science ®Google Scholar
• Suarez-Barrientos A, Wong J, Bell A, Lyster H, Karagiannis G, Banner NR. Usefulness of rabbit anti-thymocyte globulin in patients with giant cell myocarditis. Am J Cardiol. 2015;116(3):447–451. doi:10.1016/j.amjcard.2015.04.04026048854
   PubMed Web of Science ®Google Scholar
• Ammirati E, Oliva F, Belli O, et al. Giant cell myocarditis successfully treated with antithymocyte globuline and extracorporeal membrane oxygenation for 21 days. J Cardiovasc Med (Hagerstown). 2016;17(Suppl 2):e151–e153. doi:10.2459/JCM.000000000000025025643196
   PubMedGoogle Scholar
• Jain V, Mohebtash M, Rodrigo ME, Ruiz G, Atkins MB, Barac A. Autoimmune myocarditis caused by immune checkpoint inhibitors treated with antithymocyte globulin. J Immunother. 2018;41(7):332–335. doi:10.1097/CJI.000000000000023929965858
   PubMed Web of Science ®Google Scholar
• Kim HK, Kim KI, Jung SW, et al. Successfully treated acute fulminant myocarditis induced by ulcerative colitis with extracorporeal life support and infliximab. J Cardiovasc Ultrasound. 2016;24(2):163–167. doi:10.4250/jcu.2016.24.2.16327358710
   PubMedGoogle Scholar
• Pérez AR, Fontanella GH, Nocito AL, Revelli S, Bottasso OA. Short treatment with the tumour necrosis factor-alpha blocker infliximab diminishes chronic chagasic myocarditis in rats without evidence of Trypanosoma cruzi reactivation. Clin Exp Immunol. 2009;157(2):291–299. doi:10.1111/j.1365-2249.2009.03946.x19604269
   PubMed Web of Science ®Google Scholar
• Tarrio ML, Grabie N, Bu DX, Sharpe AH, Lichtman AH. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol. 2012;188:4876–4884. doi:10.4049/jimmunol.120038922491251
   PubMed Web of Science ®Google Scholar
• Baban B, Liu JY, Qin X. Upregulation of programmed death-1 and its ligand in cardiac injury models: interaction with GADD153. PLoS One. 2015;10:1–17.
   Web of Science ®Google Scholar